352
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Characterization of the Genetic Profile of CYP2C19 in Two South African Populations

, , , , , , , , & show all
Pages 1095-1103 | Published online: 12 Aug 2010

Bibliography

  • Wester K , JonnsonAK, SigsetO, DruidH, HaggS: Incidence of fatal adverse drug reactions: a population based study.Br. J. Clin. Pharmacol.65 , 573–579 (2008).
  • Allison M : Is personalized medicine finally arriving?Nat. Biotechnol.26 , 509–517 (2008).
  • Ingelman-Sundberg M : Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, the present and future.Trends Pharmacol. Sci.25 , 193–200 (2004).
  • Oscarson M : Pharmacogenetics of drug metabolizing enzymes: importance for personalised medicine.Clin. Chem. Lab. Med.41 , 573–580 (2003).
  • Goldstein JA : Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.Br. J. Clin. Pharmacol.52 , 349–355 (2001).
  • Andersson T , FlockhartDA, GoldsteinDB et al.: Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests.Clin. Pharmacol. Ther.78 , 559–581 (2005).
  • Li-Wan-Po A , GirardT, FarndonP, CooleyC, LithgowJ: Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17.Br. J. Clin. Pharmacol.69 , 222–230 (2010).
  • Janha RE , Sisay-JoofF, Hamid-AdiamohM et al.: Effects of genetic variation at the CYP2C19/CYP2C9 locus on pharmacokinetics of chlorcycloguanil in adult Gambians.Pharmacogenomics10(9) , 1423–1431 (2009).
  • Sistonen J , FuselliS, PaloJU, ChauhanN, PadhH, SajantilaA: Pharmacogenetic variation at CYP2C9, CYP2C19 and CYP2D6 at global and microgeographic scales.Pharmacogenet. Genomics19 , 170–179 (2009).
  • Wright GEB , NiehausDJH, DrögemöllerBI, KoenL, WarnichL: Elucidation of CYP2D6 genetic diversity in a unique African population: implications for the future application of pharmacogenetics in the Xhosa population.Ann. Hum. Genet.74(4) , 340–350 (2010).
  • Mwenifumbo JC , ZhouQ, BenowitzNL, SellersEM, TyndaleRF: New CYP2A6 gene deletion and conversion variants in a population of black African descent.Pharmacogenomics11(2) , 189–198 (2010).
  • Tishkoff SA , ReedFA, FriedlaenderFR et al.: The genetic structure and history of Africans and African Americans.Science324 , 1035–1044 (2009).
  • Dandara C , MasimirembwaCM, MagimbaA et al.: Genetic polymorphism of CYP2D6 and CYP2C19 in East- and Southern African populations including psychiatric patients.Eur. J. Clin. Pharmacol.57 , 11–17 (2001).
  • Matimba A , Del-FaveroJ, van Broeckhoven C, Masimirembwa C: Novel variants of major drug-metabolizing enzyme genes in diverse African populations and their predicted functional effects. Hum. Genomics3 , 169–190 (2009).
  • Ehret C : Bantu expansions: re-envisioning a central problem of early African history.Int. J. Afr. Hist. Stud.34 , 5–41 (2001).
  • Lane AB , SoodyallH, ArndtS et al.: Genetic substructure in South African Bantu-speakers: evidence from autosomal DNA and Y-chromosome studies.Am. J. Phys. Anthropol.119 , 175–185 (2002).
  • Patterson N , PetersenDC, van der Ross RE et al.: Genetic structure of a unique admixed population: implications for medical research. Hum. Mol. Genet.19 , 411–419 (2010).
  • Miller SA , DykesDD, PoleskyHF: A simple salting out procedure for extracting DNA from human nucleated cells.Nucleic Acids Res.16 , 1215 (1988).
  • Ng PC , HenikoffS: SIFT: Predicting amino acid changes that affect protein function.Nucleic Acids Res.31 , 3812–3814 (2003).
  • Ramensky V , BorkP, SunyaevS: Human non-synonymous SNPs: server and survey.Nucleic Acids Res.30 , 3894–3900 (2002).
  • Brunak S , EngelbrechtJ, KnudsenS: Prediction of human mRNA donor and acceptor sites from the DNA sequence.J. Mol. Biol.220 , 49–65 (1991).
  • Dogan RI , GetoorL, WilburWJ, MountSM: SplicePort: an interactive splice-site analysis tool.Nucleic Acids Res.35 , 285–291 (2007).
  • Kel AE , GösslingE, ReuterI, CheremushkinE, Kel-MargoulisOV, WingenderE: MATCH: a tool for searching transcription factor binding sites in DNA sequences.Nucleic Acids Res.31 , 3576–3579 (2003).
  • Quandt K , FrechK, KarasH, WingenderE, WernerT: MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data.Nucleic Acids Res.23 , 4878–4884 (1995).
  • Zuker M : Mfold web server for nucleic acid folding and hybridization prediction.Nucleic Acids Res.31 , 3406–3415 (2003).
  • Barrett JC , FryB, MallerJ, DalyMJ: Haploview: analysis and visualization of LD and haplotype maps.Bioinformatics21 , 263–265 (2005).
  • Guengerich PF : Human cytochrome P450 enzymes. In: Cytochrome P450: Structure, Mechanism and Biochemistry. 3rd Edition. Oritz de Montellano PR (Ed.). Plenum Publishers, NY, USA, 378 (2005).
  • Kearns GL , LeederJS, GaedigkA: Impact of the CYP2C19*17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effect.Drug Metab. Dispos.38(6) , 894–897 (2010).
  • Gaedigk A , CoetseeC: The CYP2D6 gene locus in South African Coloureds: unique allele distributions, novel alleles and gene arrangements.Eur. J. Clin. Pharmacol.64 , 465–475 (2008).
  • Arefayene M , SkaarTC, ZhaoX et al.: Sequence diversity and functional characterization of the 5´-regulatory region of human CYP2C19.Pharmacogenetics13 , 199–206 (2003).
  • Chen Y , GoldsteinJA: The transcriptional regulation of the human CYP2C genes.Curr. Drug Metab.10 , 567–578 (2009).
  • Bhat R , WeaverJA, SterlingKM, BresnickE: Nuclear transcription factor Oct-1 binds to the 5´ upstream region of CYP1A1 and negatively regulates its expression.Int. J. Biochem. Cell Biol.28 , 217–227 (1996).
  • Fiala-Beer E , LeeAC, MurrayM: Regulation of the rat cyp2A4 gene promoter by c-Jun and octamer binding protein-1.Int. J. Biochem. Cell. Biol.39 , 1235–1247 (2007).
  • Mwinyi J , HofmannY, PedersenRS et al.: The transcription factor GATA-4 regulates cytochrome P4502C19 gene expression.Life Sci. 86 , 699–706 (2010).
  • Blaisdell J , MohrenweiserH, JacksonJ et al.: Identification and functional characterization of new potentially defective alleles of human CYP2C19.Pharmacogenetics12 , 703–711 (2002).
  • Rasmussen H , WergeT: Misclassification of allele CYP2C19*10 as CYP2C19*2 by a commonly used PCR-RFLP procedure.Genet. Test.12 , 57–58 (2008).
  • Ellis KJ , StoufferGA, McLeodHL, LeeCR: Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations.Pharmacogenomics10 , 1799–1817 (2009).
  • Mehta U , DurrheimDN, BlockmanM, KredoT, GoundenR, BarnesKI: Adverse drug reactions in adult medical inpatients in a South African hospital serving a community with a high HIV/AIDS prevalence: prospective observational study.Br. J. Clin. Pharmacol.65 , 396–406 (2007).
  • Jones AE , BrownKC, WernerRE et al.: Variability in drug metabolizing enzyme activity in HIV-infected patients.Eur. J. Clin. Pharmacol.66(5) , 475–485 (2010).
  • Chen L , QinS, XieJ et al.: Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China.Pharmacogenomics9 , 691–702 (2008).
  • Ragia G , ArvanitidisKI, TavridouA, ManolopoulosVG: Need for reassessment of reported CYP2C19 allele frequencies in various populations in view of CYP2C19*17 discovery: the case of Greece.Pharmacogenomics10 , 43–49 (2009).

▪ Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.